Tarsus Pharmaceuticals IncNASDAQ:TARS
- LAST PRICE32.7500
- TODAY'S CHANGE (%)0.4600 (1.4246%)
- Bid / Lots32.7500/ 1
- Ask / Lots33.5000/ 1
- Open / Previous Close32.1100 / 32.2900
- Day Range
- 52 Week Range
- Volume323,663
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | TARS |
|---|---|---|
| 09:32 ET | 1856 | 32.11 |
| 09:36 ET | 700 | 32.025 |
| 09:38 ET | 5650 | 32.38 |
| 09:39 ET | 1299 | 32.31 |
| 09:41 ET | 2761 | 32.335 |
| 09:43 ET | 3633 | 31.98 |
| 09:45 ET | 200 | 32.17 |
| 09:48 ET | 670 | 31.88 |
| 09:50 ET | 200 | 32.135 |
| 09:52 ET | 2828 | 32.13 |
| 09:54 ET | 2519 | 31.93 |
| 09:56 ET | 650 | 31.78 |
| 09:57 ET | 600 | 32.16 |
| 09:59 ET | 100 | 31.975 |
| 10:01 ET | 420 | 31.985 |
| 10:03 ET | 600 | 32 |
| 10:06 ET | 540 | 32 |
| 10:08 ET | 600 | 32.025 |
| 10:10 ET | 1300 | 32.13 |
| 10:12 ET | 646 | 32.38 |
| 10:14 ET | 878 | 32.355 |
| 10:17 ET | 347 | 32.25 |
| 10:19 ET | 300 | 32.27 |
| 10:21 ET | 300 | 32.345 |
| 10:24 ET | 800 | 32.31 |
| 10:28 ET | 200 | 32.28 |
| 10:30 ET | 700 | 32.51 |
| 10:33 ET | 200 | 32.51 |
| 10:35 ET | 400 | 32.57 |
| 10:39 ET | 100 | 32.59 |
| 10:42 ET | 400 | 32.58 |
| 10:44 ET | 100 | 32.62 |
| 10:46 ET | 300 | 32.71 |
| 10:50 ET | 600 | 32.78 |
| 10:51 ET | 234 | 32.88 |
| 10:53 ET | 904 | 32.85 |
| 10:57 ET | 350 | 32.82 |
| 11:00 ET | 200 | 32.8 |
| 11:06 ET | 700 | 32.96 |
| 11:08 ET | 1491 | 33.05 |
| 11:09 ET | 400 | 32.96 |
| 11:11 ET | 1097 | 32.96 |
| 11:13 ET | 400 | 32.87 |
| 11:15 ET | 600 | 32.85 |
| 11:18 ET | 100 | 32.905 |
| 11:20 ET | 1100 | 32.93 |
| 11:22 ET | 400 | 32.97 |
| 11:24 ET | 200 | 32.89 |
| 11:26 ET | 100 | 32.92 |
| 11:27 ET | 100 | 32.84 |
| 11:31 ET | 100 | 32.96 |
| 11:33 ET | 100 | 32.96 |
| 11:36 ET | 600 | 32.92 |
| 11:38 ET | 1014 | 32.94 |
| 11:40 ET | 100 | 32.975 |
| 11:44 ET | 426 | 32.97 |
| 11:49 ET | 100 | 32.96 |
| 11:51 ET | 200 | 32.975 |
| 11:54 ET | 423 | 32.97 |
| 11:56 ET | 600 | 32.91 |
| 11:58 ET | 2400 | 32.975 |
| 12:00 ET | 700 | 33 |
| 12:02 ET | 300 | 33.06 |
| 12:03 ET | 938 | 33.065 |
| 12:05 ET | 200 | 33.05 |
| 12:07 ET | 300 | 32.99 |
| 12:09 ET | 200 | 32.97 |
| 12:12 ET | 1500 | 32.94 |
| 12:14 ET | 100 | 32.9 |
| 12:16 ET | 300 | 32.94 |
| 12:18 ET | 400 | 32.87 |
| 12:20 ET | 400 | 32.81 |
| 12:21 ET | 2028 | 32.83 |
| 12:23 ET | 300 | 32.86 |
| 12:25 ET | 100 | 32.87 |
| 12:27 ET | 100 | 32.88 |
| 12:30 ET | 200 | 32.87 |
| 12:32 ET | 416 | 32.83 |
| 12:36 ET | 4700 | 32.89 |
| 12:38 ET | 500 | 33 |
| 12:39 ET | 100 | 33.03 |
| 12:41 ET | 2738 | 33.08 |
| 12:43 ET | 1100 | 32.98 |
| 12:45 ET | 100 | 32.98 |
| 12:48 ET | 961 | 32.895 |
| 12:50 ET | 200 | 32.9 |
| 12:52 ET | 100 | 32.93 |
| 12:54 ET | 200 | 32.87 |
| 12:56 ET | 200 | 32.93 |
| 12:57 ET | 400 | 32.865 |
| 12:59 ET | 100 | 32.865 |
| 01:01 ET | 100 | 32.81 |
| 01:03 ET | 900 | 32.83 |
| 01:06 ET | 100 | 32.805 |
| 01:08 ET | 100 | 32.76 |
| 01:10 ET | 1700 | 32.855 |
| 01:12 ET | 1900 | 32.855 |
| 01:14 ET | 200 | 32.8 |
| 01:15 ET | 400 | 32.755 |
| 01:17 ET | 200 | 32.74 |
| 01:21 ET | 100 | 32.755 |
| 01:26 ET | 700 | 32.72 |
| 01:28 ET | 513 | 32.76 |
| 01:32 ET | 1249 | 32.69 |
| 01:35 ET | 400 | 32.69 |
| 01:37 ET | 714 | 32.74 |
| 01:39 ET | 2786 | 32.74 |
| 01:42 ET | 1800 | 32.72 |
| 01:44 ET | 800 | 32.73 |
| 01:46 ET | 300 | 32.73 |
| 01:48 ET | 600 | 32.75 |
| 01:50 ET | 400 | 32.79 |
| 01:51 ET | 101 | 32.76 |
| 01:53 ET | 214 | 32.78 |
| 01:55 ET | 400 | 32.84 |
| 01:57 ET | 504 | 32.845 |
| 02:00 ET | 300 | 32.845 |
| 02:04 ET | 400 | 32.85 |
| 02:06 ET | 200 | 32.87 |
| 02:08 ET | 100 | 32.88 |
| 02:09 ET | 2394 | 32.965 |
| 02:11 ET | 300 | 33.02 |
| 02:15 ET | 100 | 33.03 |
| 02:18 ET | 343 | 32.9959 |
| 02:20 ET | 940 | 33.01 |
| 02:22 ET | 775 | 32.94 |
| 02:26 ET | 100 | 32.94 |
| 02:27 ET | 1483 | 32.975 |
| 02:29 ET | 700 | 32.92 |
| 02:31 ET | 1100 | 32.9899 |
| 02:33 ET | 1400 | 33.06 |
| 02:36 ET | 1113 | 33.11 |
| 02:38 ET | 400 | 33.155 |
| 02:40 ET | 249 | 33.15 |
| 02:42 ET | 200 | 33.19 |
| 02:45 ET | 650 | 33.18 |
| 02:47 ET | 1057 | 33.18 |
| 02:49 ET | 700 | 33.16 |
| 02:54 ET | 1321 | 33.18 |
| 02:58 ET | 2552 | 33.12 |
| 03:00 ET | 100 | 33.115 |
| 03:02 ET | 474 | 33.11 |
| 03:03 ET | 216 | 33.115 |
| 03:05 ET | 100 | 33.14 |
| 03:07 ET | 100 | 33.11 |
| 03:09 ET | 1141 | 33.095 |
| 03:12 ET | 840 | 33.13 |
| 03:16 ET | 100 | 33.105 |
| 03:21 ET | 1100 | 33.065 |
| 03:23 ET | 100 | 33.075 |
| 03:25 ET | 1978 | 33.165 |
| 03:27 ET | 200 | 33.2 |
| 03:30 ET | 400 | 33.21 |
| 03:32 ET | 3174 | 33.27 |
| 03:34 ET | 728 | 33.275 |
| 03:36 ET | 5945 | 33.19 |
| 03:38 ET | 400 | 33.16 |
| 03:39 ET | 500 | 33.15 |
| 03:41 ET | 2641 | 33.025 |
| 03:43 ET | 1859 | 32.95 |
| 03:45 ET | 1287 | 32.94 |
| 03:48 ET | 3892 | 33.03 |
| 03:50 ET | 400 | 33.05 |
| 03:52 ET | 1611 | 33.145 |
| 03:54 ET | 4045 | 33.12 |
| 03:56 ET | 3470 | 33.01 |
| 03:57 ET | 3385 | 32.885 |
| 03:59 ET | 69993 | 32.75 |
Sep 25, 2024
Tarsus to Participate in Fireside Chat at UBS Virtual Ophthalmology Day 2024, from 5:00PM ET on Wednesday Sep 25, 2024 by Dow Jones
5:00PM ET on Wednesday Sep 25, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Tarsus Pharmaceuticals Inc | 1.2B | -7.4x | --- |
Enliven Therapeutics Inc | 1.2B | -13.1x | --- |
Day One Biopharmaceuticals Inc | 1.2B | -7.0x | --- |
Tyra Biosciences Inc | 1.2B | -13.2x | --- |
Bicara Therapeutics Inc | 1.2B | -18.5x | --- |
Cogent Biosciences Inc | 1.2B | -4.3x | --- |
Company Information
Tarsus Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics, starting with eye care. The Company’s lead product candidate, XDEMVY is a lotilaner ophthalmic solution that targets and eradicates the root cause of Demodex blepharitis, Demodex mite infestation. The active pharmaceutical ingredient (API) of XDEMVY, lotilaner, paralyzes and eradicates mites and other parasites through the inhibition of parasite-specific gamma-aminobutyric acid-gated chloride channels. The Company investigating the development of its product candidates to address targeted diseases with high unmet medical needs, which include TP-03 for the potential treatment of Meibomian Gland Disease (MGD), TP-04, a novel gel formulation of lotilaner for the potential treatment of rosacea, and TP-05, a novel investigative oral formulation of lotilaner, for potential Lyme disease prophylaxis and community malaria reduction.
Contact Information
- Headquarters
- 15440 Laguna Canyon RoadIRVINE, CA, United States 92618
- Phone
- 949-409-9820
- Fax
- 302-531-3150
Executives
- Chairman of the Board, President, Chief Executive Officer, Co-Founder
- Bobak Azamian
- Chief Financial Officer and Chief Strategy Officer
- Jeffrey Farrow
- Chief Operating Officer
- Seshadri Neervannan
- Chief Human Resources Officer
- Dianne Whitfield
- General Counsel, Secretary
- Bryan Wahl
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.2B |
|---|---|
Revenue (TTM) | $83.4M |
Shares Outstanding | 38.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.08 |
EPS | $-4.43 |
Book Value | $5.76 |
P/E Ratio | -7.4x |
Price/Sales (TTM) | 14.7 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -189.89% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
